Print this page
-
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma
Protocol: 102104Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Cervix
Other Female Genital
Corpus Uteri -
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer.
Protocol: 102204Principal Investigator:
- Mark Einstein M.D (New Jersey Medical School)
Applicable Disease Sites: Ovary -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
- Saum Ghodoussipour (Rutgers University)
Applicable Disease Sites: Other Female Genital
Other Male Genital
Urinary Bladder -
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-ZZFX (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Protocol: 102301Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Other Female Genital -
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature? Status.
Protocol: 102302Principal Investigator:
- Aliza Leiser (Rutgers University)
Applicable Disease Sites: Other Female Genital -
A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers
Protocol: 102304Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Ovary